Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) EBT (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed EBT for 9 consecutive years, with -$128.4 million as the latest value for Q4 2025.

  • Quarterly EBT fell 12.0% to -$128.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$512.4 million through Dec 2025, down 21.23% year-over-year, with the annual reading at -$512.4 million for FY2025, 21.23% down from the prior year.
  • EBT for Q4 2025 was -$128.4 million at Denali Therapeutics, down from -$126.9 million in the prior quarter.
  • The five-year high for EBT was $183.4 million in Q2 2023, with the low at -$133.0 million in Q1 2025.
  • Average EBT over 5 years is -$84.9 million, with a median of -$100.6 million recorded in 2023.
  • The sharpest move saw EBT skyrocketed 412.05% in 2023, then crashed 154.0% in 2024.
  • Over 5 years, EBT stood at -$75.8 million in 2021, then tumbled by 30.13% to -$98.7 million in 2022, then fell by 21.04% to -$119.4 million in 2023, then grew by 3.98% to -$114.7 million in 2024, then decreased by 12.0% to -$128.4 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$128.4 million, -$126.9 million, and -$124.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.